shanghai fosun pharmaceutical group - SFOSF

SFOSF

Close Chg Chg %
1.78 0.00 0.00%

Open Market

1.78

0.00 (0.00%)

Volume: 2.81K

Last Updated:

Dec 20, 2024, 9:30 AM EDT

Company Overview: shanghai fosun pharmaceutical group - SFOSF

SFOSF Key Data

Open

$1.78

Day Range

1.78 - 1.78

52 Week Range

1.50 - 2.24

Market Cap

$4.87B

Shares Outstanding

2.66B

Public Float

N/A

Beta

0.58

Rev. Per Employee

N/A

P/E Ratio

16.59

EPS

$0.11

Yield

209.79%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

171.67

 

SFOSF Performance

1 Week
 
0.00%
 
1 Month
 
-11.00%
 
3 Months
 
9.88%
 
1 Year
 
-27.27%
 
5 Years
 
N/A
 

SFOSF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About shanghai fosun pharmaceutical group - SFOSF

Shanghai Fosun Pharmaceutical Group Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products and medical equipment, import and export of medical equipment, healthcare services, and the provision of related and other consulting services and investment management. It operates through the following business segment: Pharmaceutical Manufacturing and R&D; Healthcare Service; Medical Devices and Medical Diagnosis; Pharmaceutical Distribution and Retail; and Other Business Operations. The Pharmaceutical Manufacturing and R&D segment involves in the production, sale, and research of medicine. The Healthcare Service segment provides healthcare service and hospital management. The Medical Devices and Medical Diagnosis segment focuses on the production and sale of medical equipment and diagnostic products. The Pharmaceutical Distribution and Retail segment issue retail and wholesale of medicine. The Other Business Operations segment comprises business that is different from the role of other segments. The company was founded on January 14, 1994 and is headquartered in Shanghai, China.

SFOSF At a Glance

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Building A
Shanghai, Shanghai 200233
Phone 86-21-3398-7870 Revenue 5.80B
Industry Pharmaceuticals: Major Net Income 336.66M
Sector Health Technology Employees 40,370
Fiscal Year-end 12 / 2024
View SEC Filings

SFOSF Valuation

P/E Current 16.591
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 17.265
Price to Sales Ratio 1.001
Price to Book Ratio 0.903
Price to Cash Flow Ratio 9.438
Enterprise Value to EBITDA 18.226
Enterprise Value to Sales 1.756
Total Debt to Enterprise Value 0.494

SFOSF Efficiency

Revenue/Employee 143,793.825
Income Per Employee 8,339.254
Receivables Turnover 4.246
Total Asset Turnover 0.368

SFOSF Liquidity

Current Ratio 1.001
Quick Ratio 0.778
Cash Ratio 0.462

SFOSF Profitability

Gross Margin 43.783
Operating Margin 2.052
Pretax Margin 2.625
Net Margin 5.799
Return on Assets 2.137
Return on Equity 5.238
Return on Total Capital 2.933
Return on Invested Capital 3.985

SFOSF Capital Structure

Total Debt to Total Equity 78.208
Total Debt to Total Capital 43.886
Total Debt to Total Assets 31.333
Long-Term Debt to Equity 34.047
Long-Term Debt to Total Capital 19.105
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Shanghai Fosun Pharmaceutical Group - SFOSF

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
4.36B 6.01B 6.49B 5.80B
Sales Growth
+6.35% +37.90% +8.01% -10.60%
Cost of Goods Sold (COGS) incl D&A
2.07B 3.27B 3.62B 3.26B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
250.37M 302.11M 363.49M 440.18M
Depreciation
161.08M 190.14M 201.14M 230.15M
Amortization of Intangibles
80.32M 94.29M 145.76M 188.36M
COGS Growth
+16.51% +58.41% +10.45% -9.78%
Gross Income
2.29B 2.74B 2.88B 2.54B
Gross Income Growth
-1.41% +19.40% +5.10% -11.64%
Gross Profit Margin
+52.58% +45.52% +44.30% +43.78%
2020 2021 2022 2023 5-year trend
SG&A Expense
1.95B 2.38B 2.40B 2.40B
Research & Development
376.43M 556.55M 581.26M 527.14M
Other SG&A
1.58B 1.82B 1.82B 1.88B
SGA Growth
-2.56% +21.63% +1.06% +0.11%
Other Operating Expense
8.95M 8.66M 10.61M 17.60M
Unusual Expense
(70.90M) 96.18M 400.58M 71.64M
EBIT after Unusual Expense
399.76M 254.82M 62.78M 47.49M
Non Operating Income/Expense
179.27M 538.61M 491.39M 297.00M
Non-Operating Interest Income
34.52M 55.42M 51.32M 59.97M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
130.26M 132.17M 147.38M 192.09M
Interest Expense Growth
-17.64% +1.47% +11.51% +30.34%
Gross Interest Expense
132.66M 135.97M 154.17M 199.03M
Interest Capitalized
2.40M 3.80M 6.80M 6.93M
Pretax Income
448.77M 661.26M 406.79M 152.39M
Pretax Income Growth
+0.21% +47.35% -38.48% -62.54%
Pretax Margin
+10.29% +11.00% +6.26% +2.63%
Income Tax
106.90M 165.35M 93.10M 52.15M
Income Tax - Current - Domestic
123.80M 157.57M 121.09M 74.69M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(16.90M) 7.78M (27.99M) (22.54M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - (148.28K)
-
Consolidated Net Income
570.83M 773.32M 586.22M 408.47M
Minority Interest Expense
40.16M 39.10M 32.18M 71.81M
Net Income
530.67M 734.22M 554.05M 336.66M
Net Income Growth
+10.39% +38.36% -24.54% -39.24%
Net Margin Growth
+12.17% +12.21% +8.53% +5.80%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
530.67M 734.22M 554.05M 336.66M
Preferred Dividends
- - - -
-
Net Income Available to Common
530.67M 734.22M 554.05M 336.66M
EPS (Basic)
0.2071 0.2865 0.2125 0.1261
EPS (Basic) Growth
+10.39% +38.34% -25.83% -40.66%
Basic Shares Outstanding
2.56B 2.56B 2.61B 2.67B
EPS (Diluted)
0.2071 0.2865 0.2125 0.1261
EPS (Diluted) Growth
+10.39% +38.34% -25.83% -40.66%
Diluted Shares Outstanding
2.56B 2.56B 2.61B 2.67B
EBITDA
579.24M 653.11M 826.85M 559.31M
EBITDA Growth
+6.53% +12.75% +26.60% -32.36%
EBITDA Margin
+13.29% +10.86% +12.73% +9.64%

Shanghai Fosun Pharmaceutical Group in the News